EUVIMEDEUVIMED entdecken
Open Access

Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease

Jianyi Yin iD, Yassin El-Najjar, Noelle Cordova, Mary-Joe Touma, Noelle Nguyen, Moheb Boktor, Ezra Burstein, David I Fudman iD

Inflammatory Bowel Diseases · 03.10.2024 · 30 (10) · 1914-1916

DOI: 10.1093/ibd/izae105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 20.05.2024. Verfasst von Jianyi Yin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Remission Induction, Heterocyclic Compounds, 3-Ring, Inflammatory Bowel Diseases, Drug Therapy, Combination. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lay Summary We report that upadacitinib intended for short-term use in combination with biologic therapy appeared to be effective in inducing steroid-free clinical remission in patients with active inflammatory bowel disease, but a substantial proportion of patients required extended use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Remission InductionHeterocyclic Compounds, 3-RingInflammatory Bowel DiseasesDrug Therapy, CombinationHumansFemaleMaleAdultMiddle AgedTreatment OutcomeBiological Therapy

Stichwörter der Autor:innen

JAK inhibitorbiologic therapyinflammatory bowel diseaseupadacitinib

Substanzen

upadacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • University of Houston College of Pharmacy, Houston, TX, USA.

ORCID-Profile: Jianyi Yin, David I Fudman

Förderung

  • NIDDK NIH HHS
  • NIH

Zitieren

APA

Yin, J., El-Najjar, Y., Cordova, N., Touma, M. J., Nguyen, N., Boktor, M., Burstein, E., & Fudman, D. I. (2024). Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 30(10), 1914-1916. https://doi.org/10.1093/ibd/izae105

Vancouver

Yin J, El-Najjar Y, Cordova N, Touma MJ, Nguyen N, Boktor M, et al. Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2024;30(10):1914-1916. doi:10.1093/ibd/izae105

BibTeX
@article{Yin2024,
  author = {Yin, Jianyi and El-Najjar, Yassin and Cordova, Noelle and Touma, Mary-Joe and Nguyen, Noelle and Boktor, Moheb and Burstein, Ezra and Fudman, David I},
  title = {Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {10},
  pages = {1914--1916},
  doi = {10.1093/ibd/izae105}
}
Kostenlos starten →